Conference abstract · 26 Jan 2021
Conference abstractPublished 2019
The keys to manufacturing viral vaccines for individual human population
Rangsit University, Thailand
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The success to use subunit viral vaccine to prevent a particular viral infection is very limit. This is different from the time when the entire Cowpox virus was originally used for vaccination to prevent the smallpox viral epidemic over a thousand years ago in China before approved in a scientific way by Edward Jenner although immunity was not known. Knowledge of immunology has been profoundly discovered now-a-days. With a thought of safety reason to prevent side effects, subunit viral vaccine becomes the major choice for manufacturing viral vaccine. However, many kinds of viral vaccines could not reach our accomplishment. There is a question why viral vaccines cannot be effective for everybody. This is a question that we need to revise our knowledge and manipulate in the right direction for the viral vaccine production. To prevent a viral infection, a body must produce a protective antibody to prevent the particular viral particle to attach the viral receptor on a target cell. Theoretically, adaptive immunity needs induction not only by a particular antigen but also our cellular molecule called major histocompatibility complex (MHC) to form a complex molecule with its appropriate epitope to activate a specific receptor of T cell. There are two classes of MHC molecules called class I and class II. MHC class I is required for inducing cytotoxic T cell while MHC class II is for helper T cell. Helper T cell plays a key role to induce an effective stage of acquired immunity including a specific protective antibody. To produce the viral-specific antibody, MHC class II plays a key role to induce helper T cell and then B cell to synthesize a specific antibody. Since the MHC gene alleles are highly polymorphic so the possibility that individuals have the same gene alleles might be one in a million which, mostly, can be found in those who are an identical twin. Accordingly, a subunit viral vaccine, which contains a limit number of epitopes, would reduce a capacity of an antigen presenting cell, such as a dendritic cell, to process some epitopes to induce the particular helper T cell clones. Subsequently, in some people, the corresponding B cell clones cannot synthesize the specific antibody to neutralize the particular infectious viral particle. Moreover, the success of vaccination might require other different thoughts. We might need to understand more about the viral receptor on the target cells. There was a proposal of an inducible viral receptor concept which can be applied to protect viral infection as an additional strategy to produce the effective viral vaccines. Accordingly, this presentation will present the novel approach to develop the viral vaccine for everybody.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 15 Oct 2018
The key to Manufacturing Viral Vaccines for individual Human Population
Short communication · 25 Dec 2020
The explanations to developed viral vaccines for individual human population
Conference abstract · 23 Mar 2022
Early proof of concept with human viral challenge models in vaccine development
Short communication · 22 Jun 2018
Early proof of concept with human viral challenge models in vaccine development
More from this journal
The newest in Journal of Pharmaceutics & Drug Delivery Research.
Research article · 12 Jun 2025
Melt-in-Mouth Miracles: A New Era of Drug Delivery with Mouth Dissolving Tablets
Research article · 20 Feb 2025
Sustained Drug Delivery in Pharmaceutical Dosage Forms for Novel Approaches of Formulation Design
Research article · 23 Jan 2025
Cutting Out Counterfeits: How Blockchain Can Revolutionize Drug Traceability?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutics & Drug Delivery Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Tirasak Pasharawipas”

